Page 72 - Read Online

Lin et al. Cancer Drug Resist. 2026;9:14 Page 17 of 19

31. Li P, Huang T, Zou Q, et al. FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK/STAT3 signaling pathway. J
Immunol 2019;202:3065-75. DOI PubMed
32. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular
signaling proteins. Science 1994;264:1415-21. DOI PubMed
33. Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov
2017;7:188-201. DOI PubMed PMC
34. Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature
2017;547:413-8. DOI PubMed PMC
35. Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 2020;20:25-39. DOI PubMed PMC
36. Xue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal
Transduct Target Ther 2025;10:106. DOI PubMed PMC
37. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5. DOI
PubMed
38. Castagnoli L, Cancila V, Cordoba-Romero SL, et al. WNT signaling modulates PD-L1 expression in the stem cell compartment of
triple-negative breast cancer. Oncogene 2019;38:4047-60. DOI PubMed PMC
39. Huang T, Li F, Cheng X, et al. Wnt inhibition sensitizes PD-L1 blockade therapy by overcoming bone marrow-derived
myofibroblasts-mediated immune resistance in tumors. Front Immunol 2021;12:619209. DOI PubMed PMC
40. Wang H, Luo K, Zhan Y, Peng S, Fan S, Wang W. Role of β-catenin in PD-L1 expression of nasopharyngeal carcinoma. Heliyon
2023;9:e18130. DOI PubMed PMC
41. Sayaman RW, Saad M, Thorsson V, et al. Germline genetic contribution to the immune landscape of cancer. Immunity
2021;54:367-86.e8. DOI PubMed PMC
42. Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent
PI3K/Akt signalling', new targets for cancer therapy. Mol Cancer 2018;17:37. DOI PubMed PMC
43. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 2016;27:409-16.
DOI PubMed
44. Bergholz JS, Wang Q, Wang Q, et al. PI3Kβ controls immune evasion in PTEN-deficient breast tumours. Nature 2023;617:139-46. DOI
PubMed PMC
45. Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
Nature 2012;482:400-4. DOI PubMed PMC
46. Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res
2014;2:361-70. DOI PubMed PMC
47. Cui JW, Li Y, Yang Y, et al. Tumor immunotherapy resistance: revealing the mechanism of PD-1 / PD-L1-mediated tumor immune
escape. Biomed Pharmacother 2024;171:116203. DOI PubMed
48. Crane CA, Panner A, Murray JC, et al. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.
Oncogene 2009;28:306-12. DOI PubMed PMC
49. Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016;6:202-16.
DOI PubMed PMC
50. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in
glioma. Nat Med 2007;13:84-8. DOI PubMed
51. Zhao R, Song Y, Wang Y, et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the
PI3K/Akt/mTOR signalling pathway. Cell Prolif 2019;52:e12571. DOI PubMed PMC
52. Amornsupak K, Thongchot S, Thinyakul C, et al. HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT
signaling pathway in MDA-MB-231 breast cancer cells. BMC Cancer 2022;22:578. DOI PubMed PMC
53. Guo F, Kong W, Li D, et al. M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT
pathway. Eur J Med Res 2024;29:357. DOI PubMed PMC
54. Xu Y, Xiong J, Sun X, Gao H. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer
immunotherapy. Acta Pharm Sin B 2022;12:4327-47. DOI PubMed PMC
55. Tian M, Liu X, Pei H. Nanomaterial-based cancer immunotherapy: enhancing treatment strategies. Front Chem 2024;12:1492215. DOI
PubMed PMC
56. Kateh Shamshiri M, Jaafari MR, Badiee A. Preparation of liposomes containing IFN-gamma and their potentials in cancer
immunotherapy: in vitro and in vivo studies in a colon cancer mouse model. Life Sci 2021;264:118605. DOI PubMed
57. Jesorka A, Orwar O. Liposomes: technologies and analytical applications. Annu Rev Anal Chem 2008;1:801-32. DOI PubMed
65